CMS wants to provide state Medicaid programs with a new drug price verification survey tool, require the inclusion of drug payment information in contracts between Medicaid-managed care plans and pharmacy benefit managers (PBMs), and get ahead of potential misclassifications of brand name and generic drugs so states can receive the appropriate rebate amounts they’re owed, according to CMS’ notice of proposed rulemaking (NPRM) released Tuesday (May 23). The proposed rule aims to improve the Medicaid Drug Rebate Program (MDRP) and...